Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Rhea-AI Summary

Quest Diagnostics (NYSE: DGX) unveils new confirmatory testing service for novel psychoactive substances (NPS) with 88 compounds, including xylazine and acetyl fentanyl. The Health Trends® report found xylazine in 1 in 12 specimens tested, indicating a rising polysubstance crisis in America.

Positive

• Quest Diagnostics launches a new confirmatory testing service for NPS with 88 compounds, including xylazine and acetyl fentanyl.
• The Health Trends® report found xylazine in 1 in 12 specimens tested, indicating a rising polysubstance crisis in America.
• The report provides insights into the drug crisis and its shifts from misuse of prescription opioids and fentanyl to NPS.

Negative

• Xylazine was found in 8.1% of remnant specimens tested, making it the most prevalent single NPS.
• Nearly 1 in 5 amphetamines-positive specimens showed fentanyl combining.
• Specimens in areas with demographics linked to low income levels were nearly 7 times more likely to test positive for nonprescribed fentanyl than those linked to high-income communities.

Insights

Healthcare Analyst

The unveiling of Quest Diagnostics' new confirmatory testing service for novel psychoactive substances (NPS) is a significant development in the healthcare industry, particularly in the context of the ongoing substance misuse crisis. The ability to detect a wide range of NPS, including the prevalent xylazine, has important implications for both patient care and public health initiatives. With the opioid crisis evolving, the demand for comprehensive drug testing services is likely to increase, potentially benefiting Quest Diagnostics' market position and financial performance.

From an investment perspective, this innovation may enhance Quest Diagnostics' competitive edge and could lead to an expansion of its customer base among healthcare providers. However, the cost of developing and regularly updating such advanced testing panels must be weighed against the anticipated revenue from this service. The market will also be watching how this service impacts the company's operating margins and overall profitability.

The report's findings on regional disparities in NPS positivity rates and the correlation between income levels and nonprescribed fentanyl use provide critical insights for policymakers and healthcare providers. These insights could drive targeted interventions, influencing the allocation of resources and potentially affecting healthcare stocks in the diagnostics sector.

Toxicology Expert

The technical advancements in testing for NPS, such as xylazine, using liquid chromatography and mass spectrometry, represent a leap forward in toxicology. The high prevalence of xylazine in tested specimens, particularly in combination with fentanyl, underscores the urgency of the situation. The Quest Diagnostics panel's ability to adapt to emerging drug trends by updating its testing compounds is crucial in addressing the dynamic nature of drug misuse.

For stakeholders, the implications are twofold. Firstly, there is the potential for improved patient outcomes through early detection and intervention. Secondly, the data generated from these tests could inform broader public health strategies. The report's findings on the decline in heroin use and the rise in fentanyl and xylazine misuse may signal shifts in the illicit drug market, which could have wide-reaching consequences for healthcare systems and communities.

Financial Analyst

The introduction of Quest Diagnostics' NPS testing service may have a ripple effect on the company's financial health and stock performance. The report highlights a growing market need for advanced diagnostic services, which could translate into increased testing volumes and revenue growth for Quest. The strategic focus on periodic updates to the test panel aligns with the evolving nature of NPS, potentially offering a sustainable revenue stream.

Investors should consider the long-term cost implications of maintaining and updating the testing service against the backdrop of the healthcare sector's regulatory environment and reimbursement policies. Additionally, the ability of Quest Diagnostics to capitalize on this service will depend on its integration into clinical practice and acceptance by healthcare providers.

While the report provides a snapshot of the current drug misuse landscape, it is also indicative of potential future trends that could impact the healthcare and pharmaceutical industries. The data may influence drug development priorities, healthcare resource allocation and ultimately, the stock market's valuation of companies like Quest Diagnostics.

Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis

SECAUCUS, N.J., Dec. 19, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today unveiled its new confirmatory testing service for novel psychoactive substances (NPS). The new panel, which tests for 88 compounds, covers a broad array of drug classes, such as designer opioids, designer benzodiazepines, designer stimulants, fentanyl analogs, synthetic cannabinoids, and other illicit additives. Two of these classes are rapidly accelerating America's overdose crisis: other illicit additives (xylazine) and fentanyl analogs (acetyl fentanyl). The new test panel is designed to help healthcare providers detect potential drug misuse in patients prescribed controlled medications, such as opioids and other substances, amid a proliferation of synthetic or "designer" drugs in the nation's drug supply.

NPS are versions of established prescription and illicit drugs that are routinely chemically altered to enhance drug effects and evade tracking by law enforcement. As their chemical composition frequently evolves, conventional point-of-care and laboratory test methods may fail to detect NPS, increasing risks for individual patients and challenging efforts to understand their long-term health effects or prevalence in communities.

The Quest panel uses definitive liquid chromatography with advanced tandem mass spectrometry-based testing to establish NPS misuse. Quest's team of toxicologists, medical experts and data analysts will periodically review and update the panel to include the most relevant and prevalent substances present in communities, as reflected by trends in the company's nationally representative Health Trends® dataset and the latest reports from public health, academic research and law enforcement organizations.

Quest developed the panel to address the changing drug epidemic, as revealed by its nationally representatives Health Trends® report, "Drug Misuse in America 2023: The Growing Crisis of Novel Psychoactive Substances." Based on more than 3.6 million clinical laboratory drug tests performed by Quest Diagnostics in 2022, the report provides insights into the drug crisis and its shifts from misuse of prescription opioids and fentanyl to NPS. The report also includes analysis of 3,730 randomly selected "remnant" specimens tested using a pilot version of the new NPS test panel.

Approximately 13.1% of remnant specimens tested were positive for at least one NPS. Of these, the animal tranquilizer xylazine was found in 8.1%, or nearly 1 in 12 specimens tested, making it the most prevalent single NPS. Yet, non-xylazine substances, including fentanyl analogs and designer benzodiazepines, were found in 5% of remnant specimens tested, or roughly 40% of all NPS-positive test results.

These findings align with a recent report from the U.S. Centers for Disease Control and Prevention (CDC) highlighting the increasing connection between xylazine and opioid overdose deaths while also revealing growing misuse of other NPS.

Additional key findings include:

• Xylazine positivity among fentanyl-positive specimens was most prevalent in the Southeast (~90%), Northeast (~80%) and Eastern (~60%) U.S. regions. Results in the Southwest (<30%) and on the West Coast (<20%) suggest xylazine has yet to fully penetrate these U.S. regions.
• One third (32.7%) of fentanyl positive specimens were also positive for xylazine and nearly all (97.7%) specimens positive for xylazine were also positive for fentanyl.
• Nearly 1 in 5 (19%) amphetamines-positive specimens showed fentanyl combining.
• Heroin use rapidly declined, as positivity overall fell from 1.1% in 2021 to 0.4% in 2022.

The Health Trends analysis also found that specimens in areas with demographics linked to low income levels were nearly 7 times more likely to test positive for nonprescribed fentanyl than those linked to high-income communities. The researchers theorize that these differences are due to comparatively higher quality of care and generally greater access to resources in high-income communities. 

To access the full Health Trends report, click here.

"Our Health Trends data demonstrates the importance of considering all possible NPS, not just xylazine, in clinical drug testing," said Harvey W. Kaufman, M.D., medical director and head of the Health Trends research program. "The faster public health and policy makers catch up with the growing problem of synthetic drugs, the greater the likelihood of curbing a dangerous and evolving drug epidemic before more lives are lost and more families and communities suffer irreversible harm."

For more information, please visit www.QuestDrugMonitoring.com.

Quest Diagnostics Health Trends studies are performed on aggregate deidentified laboratory data in compliance with applicable privacy regulations and the company's strict privacy policies, and follow procedures approved by the WCG Institutional Review Board. The present study's strengths include its large data set, geographic scope, and validated testing by the highly reliable mass spectrometry method. Its limitations include geographic disparities and inability to validate or contextualize test results with medical records. The terms high- and low-income communities refer to certain geographies that have median income levels that fall in the highest and lowest quintile as determined by the U.S. Census Bureau. For the full study methodology, including strengths and weaknesses, please refer to the full report.

About Quest Diagnostics Health Trends®
Quest Diagnostics Health Trends® is a series of scientific reports that provide insights into health issues, based on patient laboratory data, to empower better patient care, population health management and public health policy. The reports are based on the HIPAA-compliant Quest Diagnostics database of more than 60 billion deidentified laboratory test datapoints. The Quest database is believed to be the largest of its kind in healthcare. Health Trends research has yielded novel insights into allergies and asthma, cancer, COVID-19, diabetes, heart disease, hepatitis, influenza, Lyme disease, prescription drug misuse and workplace wellness. Quest Diagnostics also produces the Drug Testing Index (DTI)™, a series of reports on national workplace drug positivity trends based on the company's employer workplace drug testing data.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-launches-new-88-compound-novel-psychoactive-substance-test-panel-302019063.html

SOURCE Quest Diagnostics

FAQ

What is the new confirmatory testing service unveiled by Quest Diagnostics (NYSE: DGX)?

Quest Diagnostics has launched a new confirmatory testing service for novel psychoactive substances (NPS) with 88 compounds, including xylazine and acetyl fentanyl.

What did the Health Trends® report find about xylazine?

The report found xylazine in 1 in 12 specimens tested, indicating a rising polysubstance crisis in America.

How prevalent was xylazine in the specimens tested?

Xylazine was found in 8.1% of remnant specimens tested, making it the most prevalent single NPS.

What are some negative findings from the report?

Nearly 1 in 5 amphetamines-positive specimens showed fentanyl combining. Specimens in areas with demographics linked to low income levels were nearly 7 times more likely to test positive for nonprescribed fentanyl than those linked to high-income communities.